The Abeta peptide is widely considered a major cause of Alzheimer's disease since it causes neuronal death in an oligomerisation-dependent manner. In order to identify new inhibitors of Abeta that may be chemo preventative for Alzheimer's disease, a yeast assay that qualitatively determines the amounts and state of the human Abeta42 peptide has been developed. Yeast assays such as this can be applied to studies on aggregation toxicity, autophagic responses and drug screening in Alzheimer's disease.
↧